表紙
市場調査レポート

AIMM Therapeutics B.V.:パイプライン製品分析

AIMM Therapeutics B.V. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 276013
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
AIMM Therapeutics B.V.:パイプライン製品分析 AIMM Therapeutics B.V. - Product Pipeline Review - 2016
出版日: 2016年02月24日 ページ情報: 英文 41 Pages
概要

AIMM Therapeutics B.V.では、がんや感染症、炎症性疾患、自己免疫疾患などの治療用の人体向けモノクローナル抗体を開発しています。また、(先の諸疾患を含めた)医療上のニーズのある疾患の予防・診断に向けた研究プログラムを推進しています。同社では自社開発したAIMSelect技術を用いて、個人のB細胞の不死化・選別を行い、抗体の生産に役立てています。同社ではまた、AIMSelect/AIMProve技術を活用して、ヒト化マウス(ヒトの免疫系を有する専用マウスモデル)のB細胞から抗体を生産しています。

当レポートでは、オランダのバイオ医薬品企業、AIMM Therapeutics B.V.(AIMM Therapeutics)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

AIMM Therapeutics B.V.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

パイプライン製品の概要

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

薬剤のプロファイル

  • CR-8020
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • 季節性・パンデミックインフルエンザ向け血球凝集素阻害二重特異性モノクローナル抗体
  • 急性骨髄性白血病(AML)向けモノクローナル抗体
  • 結腸癌向けモノクローナル抗体
  • サイトメガロウイルス感染症向けモノクローナル抗体
  • C型肝炎向けモノクローナル抗体
  • ヒトライノウイルス感染症向けモノクローナル抗体
  • メラノーマ(黒色腫)向けモノクローナル抗体
  • MRSA感染症向けモノクローナル抗体
  • 膵臓癌向けモノクローナル抗体
  • クロストリジウム・ディフィシル感染症向けモノクローナル抗体
  • パレコウイルス感染症向けモノクローナル抗体

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

事業所および子会社

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07951CDB

Summary

Global Markets Direct's, 'AIMM Therapeutics B.V. - Product Pipeline Review - 2016', provides an overview of the AIMM Therapeutics B.V.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AIMM Therapeutics B.V., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AIMM Therapeutics B.V.
  • The report provides overview of AIMM Therapeutics B.V. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AIMM Therapeutics B.V.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AIMM Therapeutics B.V.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AIMM Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AIMM Therapeutics B.V.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AIMM Therapeutics B.V.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AIMM Therapeutics B.V. Snapshot
    • AIMM Therapeutics B.V. Overview
    • Key Information
    • Key Facts
  • AIMM Therapeutics B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • AIMM Therapeutics B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AIMM Therapeutics B.V. - Pipeline Products Glance
    • AIMM Therapeutics B.V. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • AIMM Therapeutics B.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • AIMM Therapeutics B.V. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • AIMM Therapeutics B.V. - Drug Profiles
    • CR-8020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Acute Myelocytic Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Colon Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cytomegalovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Hepatitis C Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Human Rhinovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Melanoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for MRSA Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Pancreatic Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-18
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-28
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Clostridium Difficile Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Hepatitis B Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AIMM Therapeutics B.V. - Pipeline Analysis
  • AIMM Therapeutics B.V. - Pipeline Products by Target
  • AIMM Therapeutics B.V. - Pipeline Products by Route of Administration
  • AIMM Therapeutics B.V. - Pipeline Products by Molecule Type
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action
  • AIMM Therapeutics B.V. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AIMM Therapeutics B.V., Key Information
  • AIMM Therapeutics B.V., Key Facts
  • AIMM Therapeutics B.V. - Pipeline by Indication, 2016
  • AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016
  • AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Out-Licensed Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AIMM Therapeutics B.V. - Phase II, 2016
  • AIMM Therapeutics B.V. - Preclinical, 2016
  • AIMM Therapeutics B.V. - Discovery, 2016
  • AIMM Therapeutics B.V. - Unknown, 2016
  • AIMM Therapeutics B.V. - Pipeline by Target, 2016
  • AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016
  • AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016

List of Figures

  • AIMM Therapeutics B.V. - Pipeline by Top 10 Indication, 2016
  • AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016
  • AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016
  • AIMM Therapeutics B.V. - Pipeline by Target, 2016
  • AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016
  • AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016
  • AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016
Back to Top